We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Peroxidase Mimic Outperforms Natural Horseradish Peroxidase in ELISA Test

By LabMedica International staff writers
Posted on 29 Sep 2015
A test-of-concept study demonstrated that a synthetic catalyst that mimics the action of horseradish peroxidase (HRP) could increase the sensitivity of a colorimetric enzyme-linked immunosorbent assay (ELISA) for human prostate surface antigen (PSA) by more than 110-fold.

Peroxidase mimics with dimensions on the nanoscale have received great interest as emerging artificial enzymes for biomedicine and environmental protection. More...
While a variety of peroxidase mimics have been developed recently, limited progress has been made toward improving their catalytic efficiency.

In a study published in the September 3, 2015, online edition of the journal ACS Nano, investigators at Michigan Technological University (Houghton, USA) and colleagues at Louisiana State University (Baton Rouge, USA) and the University of Texas at Dallas (USA) described a novel peroxidase mimic made by depositing Ir (iridium) atoms as ultrathin skins (a few atomic layers) on Pd (palladium) nanocubes.

These Pd–Ir nanocubes exhibited significantly enhanced efficiency, with catalytic constants more than 20- and 400-fold higher than those of an older version of Pd cubes and horseradish peroxidase (HRP), respectively.

In a proof-of-concept demonstration, the Pd–Ir nanocubes were used in a colorimetric ELISA for human prostate surface antigen (PSA). The modified assay was found to have a detection limit of 0.67 picograms per milliliter, which was about 110-fold lower than that of the conventional HRP-based ELISA using the same set of antibodies and the same procedure.

The Pd–Ir nanocubes were prepared by chemists at the Michigan Technological University. Investigators at Louisiana State University conducted theoretical calculations, and colleagues at the University of Texas at Dallas obtained high-resolution electron microscopy images.

"After surgery, it is vital to detect a tiny amount of prostate antigen, because otherwise you can get a false negative and perhaps delay treatment for cancer," said senior author Dr. Xiaohu Xia, assistant professor of chemistry at Michigan Technological University. "We wanted to develop a mimic peroxidase that was substantially more efficient than the natural peroxidase, which would lead to a more-sensitive PSA test. Our ultimate goal is to further refine our system for use in clinical diagnostic laboratories."

Related Links:

Michigan Technological University
Louisiana State University
University of Texas at Dallas



New
Gold Member
Automatic Hematology Analyzer
CF9600
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Repetitive Pipette
VWR® Stepper Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.